GlaxoSmithKline to buy San Mateo-based Sierra Oncology for $1.9B
April 13, 2022 at 10:31 AM EDT
Glaxo is paying a 39% premium for the rare cancer-focused biotech whose stock has already shot up 82% this year.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.